Literature DB >> 26631945

Variance associated with the use of relative velocity for force platform gait analysis in a heterogeneous population of clinically normal dogs.

Nicola Volstad1, Brett Nemke1, Peter Muir2.   

Abstract

Factors that contribute to variance in ground reaction forces (GRFs) include dog morphology, velocity, and trial repetition. Narrow velocity ranges are recommended to minimize variance. In a heterogeneous population, it may be preferable to minimize data variance and efficiently perform force platform gait analysis by evaluation of each individual dog at its preferred velocity, such that dogs are studied at a similar relative velocity (V*). Data from 27 normal dogs were obtained including withers and shoulder height. Each dog was trotted across a force platform at its preferred velocity, with controlled acceleration (±0.5 m/s(2)). V* ranges were created for withers and shoulder height. Variance effects from 12 trotting velocity ranges and associated V* ranges were examined using repeated-measures analysis-of-covariance. Mean bodyweight was 24.4 ± 7.4 kg. Individual dog, velocity, and V* significantly influenced GRF (P <0.001). Trial number significantly influenced thoracic limb peak vertical force (PVF) (P <0.001). Limb effects were not significant. The magnitude of variance effects was greatest for the dog effect. Withers height V* was associated with small GRF variance. Narrow velocity ranges typically captured a smaller percentage of trials and were not consistently associated with lower variance. The withers height V* range of 0.6-1.05 captured the largest proportion of trials (95.9 ± 5.9%) with no significant effects on PVF and vertical impulse. The use of individual velocity ranges derived from a withers height V* range of 0.6-1.05 will account for population heterogeneity while minimizing exacerbation of lameness in clinical trials studying lame dogs by efficient capture of valid trials.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trial; Dog; Force platform; Gait analysis; Relative velocity

Mesh:

Year:  2015        PMID: 26631945      PMCID: PMC4995596          DOI: 10.1016/j.tvjl.2015.08.014

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  27 in total

1.  Comparison of the trotting gaits of Labrador Retrievers and Greyhounds.

Authors:  J E Bertram; D V Lee; H N Case; R J Todhunter
Journal:  Am J Vet Res       Date:  2000-07       Impact factor: 1.156

2.  Force plate gait analysis at the walk and trot in dogs with low-grade hindlimb lameness.

Authors:  K Voss; J Imhof; S Kaestner; P M Montavon
Journal:  Vet Comp Orthop Traumatol       Date:  2007       Impact factor: 1.358

3.  Are sound dogs mechanically symmetric at trot? No, actually.

Authors:  G R Colborne
Journal:  Vet Comp Orthop Traumatol       Date:  2008       Impact factor: 1.358

4.  Precision and accuracy of ground reaction force normalization in a heterogeneous population of dogs.

Authors:  Ursula Krotscheck; Rory J Todhunter; Samantha A Nelson; Nathaniel B Sutter; Hussni O Mohammed
Journal:  Vet Surg       Date:  2014-04-05       Impact factor: 1.495

5.  Symmetry of hind limb mechanics in orthopedically normal trotting Labrador Retrievers.

Authors:  G Robert Colborne; Louise Good; Lucy E Cozens; Lisa S Kirk
Journal:  Am J Vet Res       Date:  2011-03       Impact factor: 1.156

6.  Variance associated with subject velocity and trial repetition during force platform gait analysis in a heterogeneous population of clinically normal dogs.

Authors:  Eric C Hans; Berdien Zwarthoed; Joseph Seliski; Brett Nemke; Peter Muir
Journal:  Vet J       Date:  2014-09-28       Impact factor: 2.688

7.  Accuracy and optimization of force platform gait analysis in Labradors with cranial cruciate disease evaluated at a walking gait.

Authors:  Richard Evans; Chris Horstman; Mike Conzemius
Journal:  Vet Surg       Date:  2005 Sep-Oct       Impact factor: 1.495

8.  Effect of carprofen, etodolac, meloxicam, or butorphanol in dogs with induced acute synovitis.

Authors:  Luc R Borer; John E Peel; Wolfgang Seewald; Peter Schawalder; David E Spreng
Journal:  Am J Vet Res       Date:  2003-11       Impact factor: 1.156

9.  A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs.

Authors:  Maria A Fahie; Girolamo A Ortolano; Vincent Guercio; Jeffrey A Schaffer; Gary Johnston; Jennifer Au; Bianca A Hettlich; Tom Phillips; Matthew J Allen; Alicia L Bertone
Journal:  J Am Vet Med Assoc       Date:  2013-11-01       Impact factor: 1.936

10.  Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis.

Authors:  Sarah Malek; Susannah J Sample; Zeev Schwartz; Brett Nemke; Peer B Jacobson; Elizabeth M Cozzi; Susan L Schaefer; Jason A Bleedorn; Gerianne Holzman; Peter Muir
Journal:  BMC Vet Res       Date:  2012-10-04       Impact factor: 2.741

View more
  3 in total

1.  Variance associated with walking velocity during force platform gait analysis of a heterogeneous sample of clinically normal dogs.

Authors:  Alexander M Piazza; Emily E Binversie; Lauren A Baker; Brett Nemke; Susannah J Sample; Peter Muir
Journal:  Am J Vet Res       Date:  2017-04       Impact factor: 1.156

2.  Kinetic gait analysis in healthy dogs and dogs with osteoarthritis: An evaluation of precision and overlap performance of a pressure-sensitive walkway and the use of symmetry indices.

Authors:  Michelle Brønniche Møller Nielsen; Tenna Pedersen; Amalie Mouritzen; Anne Desiré Vitger; Lise Nikolic Nielsen; Helle Harding Poulsen; James Edward Miles
Journal:  PLoS One       Date:  2020-12-15       Impact factor: 3.240

3.  Relationship between Ground Reaction Forces and Morpho- Metric Measures in Two Different Canine Phenotypes Using Regression Analysis.

Authors:  Giovanni Della Valle; Chiara Caterino; Federica Aragosa; Caterina Balestriere; Alfonso Piscitelli; Cristina Di Palma; Maria Pia Pasolini; Gerardo Fatone
Journal:  Vet Sci       Date:  2022-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.